Skip to content

Welcome to BioArctic’s Investor Relations page where we provide resources and information for our investors, shareholders, and financial community. BioArctic’s vision is to generate innovative drugs that improve the lives of patients with disorders of the central nervous system.

Within this section, you will find a comprehensive collection of press releases, interim reports, and a calendar of important events. These resources are designed to keep you informed and up-to-date with the latest developments, achievements, and financial performance of BioArctic.

Our press releases highlight significant milestones, regulatory updates, and key announcements that shape the future of our company. By accessing our interim reports, you can gain insights into our financial results, strategic objectives, and operational performance. Additionally, our calendar provides essential dates for upcoming events, such as earnings releases, investor conferences, and other relevant engagements.

Thank you for your continued support and interest in BioArctic. Together, we are shaping the future of healthcare.

November 14, 2024

Interim Report Q3 2024

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.

Audiocast with teleconference: at 09:30 CET the same day.

For more information, please contact:

Oskar Bosson

VP, Head of IR & Communication
+46704107180

Jiang Millington

Director Corporate Communication & Social Media
+46793399166